Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation

rituximab

Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
Aug 31, 2026, 17:11 | Voices
Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
Chokri Ben Lamine, Hematologist at King Faisal Specialist Hospital and Research Center, shared a post…
Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
Aug 29, 2026, 13:59 | Voices
Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
Eleftheria Hatzimichael, Special Secretary of the Board of Directors at Hellenic Society of Hematology, shared…
Charan Gubba: Adult ITP - A major shift in the 2026 ASH Guidelines
Aug 26, 2026, 17:39 | Science
Charan Gubba: Adult ITP - A major shift in the 2026 ASH Guidelines
Charan Gubba, Team Head at Sri Satya Sai Aarogya Pradayini, shared a post on LinkedIn…
Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV
Jun 23, 2026, 20:30 | Science
Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV
Aladdin Mohammad, Professor of Rheumatology at Lund University, shared on LinkedIn about a recent article he…
Abdul Mannan: What if Our First Move in Acquired Haemophilia A is Costing Frail Patients Time?
Jun 15, 2026, 15:31 | Voices
Abdul Mannan: What if Our First Move in Acquired Haemophilia A is Costing Frail Patients Time?
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn: "What…
What Happens When Molecular Science and Clinical Insight Move Together? - McMaster University Department of Medicine
Jun 10, 2026, 05:29 | Voices
What Happens When Molecular Science and Clinical Insight Move Together? - McMaster University Department of Medicine
McMaster University Department of Medicine shared on LinkedIn: ''What happens when molecular science and clinical…
Can Targeting Plasma Cells Finally Control Refractory TTP? - RPTH Journal
Apr 17, 2026, 15:59 | Science
Can Targeting Plasma Cells Finally Control Refractory TTP? - RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Roman Schimmer et al:…
Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Apr 15, 2026, 08:51 | Insight
Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn: ''Cold Agglutinin Disease…
Paritosh Garg: A fibrotic marrow is not always PMF
Apr 12, 2026, 14:15 | Voices
Paritosh Garg: A fibrotic marrow is not always PMF
Paritosh Garg, Associate Consultant at Fortis Memorial Research Institute, India, shared a post on LinkedIn: "A…
Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
Mar 12, 2026, 16:20 | Voices
Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
Aryabhatta Sadhu, Senior Resident Doctor at AIIMS, shared a post on LinkedIn: "This is an…
Scott E. Smith: Why Hematology Research Is the True Leader of all Medical Disciplines
Mar 3, 2026, 16:32 | Voices
Scott E. Smith: Why Hematology Research Is the True Leader of all Medical Disciplines
Scott E. Smith, Senior Vice President at Parexel, CEO and Founder at Chemosabe Consulting, Inc.,…
Heghine Khachatryan on ITP's Key Research Gaps: Biomarkers, Fatigue and Thrombosis Risk
Jan 5, 2026, 05:53 | Insight
Heghine Khachatryan on ITP's Key Research Gaps: Biomarkers, Fatigue and Thrombosis Risk
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology…
Danny Hsu: Another Excellent Post from Wolfgang Miesbach - Comparing Low and Standard Dose Rituximab in iTTP
Dec 22, 2025, 12:38 | Science
Danny Hsu: Another Excellent Post from Wolfgang Miesbach - Comparing Low and Standard Dose Rituximab in iTTP
Danny Hsu, President of THANZ, reposted from Wolfgang Miesbach on LinkedIn: "As DJ Khaled would…
Wolfgang Miesbach: Rituximab Dose Optimization in iTTP - Why Standard Dose is Preferred?
Dec 17, 2025, 23:55 | Drugs
Wolfgang Miesbach: Rituximab Dose Optimization in iTTP - Why Standard Dose is Preferred?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn: "ASH25 Data: Rituximab Dose…
ASH25 Day 3: Don’t Miss The Highlights
Dec 8, 2025, 22:24 | Insight
ASH25 Day 3: Don’t Miss The Highlights
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from…
Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Dec 7, 2025, 06:07 | Blog
Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Nishant Rajendra Tiwari, Hematology-Oncology Fellow at OU Health Stephenson Cancer Center, posted on X: ''Pre-emptive…
Archil Jaliashvili: Novel Rescue in Hyperhaemolysis Syndrome of Sickle Cell Anaemia
Sep 3, 2025, 19:18 | Science
Archil Jaliashvili: Novel Rescue in Hyperhaemolysis Syndrome of Sickle Cell Anaemia
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared on…
Benjamin Terrier: RCT Shows Rituximab Outperforms Conventional Therapy for Remission Induction in EGPA Annals of Int Med
Aug 23, 2025, 16:30 | Science
Benjamin Terrier: RCT Shows Rituximab Outperforms Conventional Therapy for Remission Induction in EGPA Annals of Int Med
Benjamin Terrier, Professor of Internal Medicine at Cochin Hospital, Paris Cité University, shared a post…
All: 18 Posts: 1 - 100
NewsFeed